Meglitinides or glinides are a class of drugs used to treat type 2 diabetes.

[1] Repaglinide (trade name Prandin)[2] gained US Food and Drug Administration approval in 1997.

Other drugs in this class include nateglinide (Starlix)[3] and mitiglinide (Glufast).

Repaglinide caused an increased incidence in male rats of benign adenomas (tumors) of the thyroid and liver.

[3] A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.